|
|
Blood, 15 March 2004, Vol. 103, No. 6, pp. 2096-2104.
Prepublished online as a Blood First Edition Paper on November 20, 2003; DOI 10.1182/blood-2003-08-2804.
 Previous Article | Table of Contents | Next Article 
HEMOSTASIS, THROMBOSIS, AND VASCULAR BIOLOGY
Characterization of the proteins released from activated platelets leads to localization of novel platelet proteins in human atherosclerotic lesions
Judith A. Coppinger,
Gerard Cagney,
Sinead Toomey,
Thomas Kislinger,
Orina Belton,
James P. McRedmond,
Dolores J. Cahill,
Andrew Emili,
Desmond J. Fitzgerald, and
Patricia B. Maguire
From the Department of Clinical Pharmacology, Royal College of Surgeons in Ireland, Dublin; Banting and Best Department of Medical Research, University of Toronto, and the Department of Molecular and Medical Genetics, University of Toronto, Ontario, Canada.
Proteins secreted by activated platelets can adhere to the vessel wall and promote the development of atherosclerosis and thrombosis. Despite this biologic significance, however, the complement of proteins comprising the platelet releasate is largely unknown. Using a proteomics approach, we have identified more than 300 proteins released by human platelets following thrombin activation. Many of the proteins identified were not previously attributed to platelets, including secretogranin III, a potential monocyte chemoattractant precursor; cyclophilin A, a vascular smooth muscle cell growth factor; calumenin, an inhibitor of the vitamin K epoxide reductase-warfarin interaction, as well as proteins of unknown function that map to expressed sequence tags. Secretogranin III, cyclophilin A, and calumenin were confirmed to localize in platelets and to be released upon activation. Furthermore, while absent in normal vasculature, they were identified in human atherosclerotic lesions. Therefore, these and other proteins released from platelets may contribute to atherosclerosis and to the thrombosis that complicates the disease. Moreover, as soluble extracellular proteins, they may prove suitable as novel therapeutic targets.
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati What's this?
Related Article in Blood Online:
-
Propelling the platelet proteome
- Andrew S. Weyrich and Guy A. Zimmerman
Blood 2004 103: 1979.
[Full Text]
[PDF]
This article has been cited by other articles:
|
|
|
|
 
G. Cagney and J. McRedmond
A Central Resource for Platelet Proteomics
Arterioscler. Thromb. Vasc. Biol.,
July 1, 2008;
28(7):
1214 - 1215.
[Full Text]
[PDF]
|
|
|
|
|
|
|
B. Terrier, M. C. Tamby, L. Camoin, P. Guilpain, C. Broussard, G. Bussone, A. Yaici, F. Hotellier, G. Simonneau, L. Guillevin, et al.
Identification of Target Antigens of Antifibroblast Antibodies in Pulmonary Arterial Hypertension
Am. J. Respir. Crit. Care Med.,
May 15, 2008;
177(10):
1128 - 1134.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
L. F. Brass, L. Zhu, and T. J. Stalker
Novel Therapeutic Targets at the Platelet Vascular Interface
Arterioscler. Thromb. Vasc. Biol.,
March 1, 2008;
28(3):
s43 - s50.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
W. Winkler, M. Zellner, M. Diestinger, R. Babeluk, M. Marchetti, A. Goll, S. Zehetmayer, P. Bauer, E. Rappold, I. Miller, et al.
Biological Variation of the Platelet Proteome in the Elderly Population and Its Implication for Biomarker Research
Mol. Cell. Proteomics,
January 1, 2008;
7(1):
193 - 203.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
G. Davi and C. Patrono
Platelet Activation and Atherothrombosis
N. Engl. J. Med.,
December 13, 2007;
357(24):
2482 - 2494.
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. A. Coppinger, R. O'Connor, K. Wynne, M. Flanagan, M. Sullivan, P. B. Maguire, D. J. Fitzgerald, and G. Cagney
Moderation of the platelet releasate response by aspirin
Blood,
June 1, 2007;
109(11):
4786 - 4792.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. O. Maree and D. J. Fitzgerald
Variable Platelet Response to Aspirin and Clopidogrel in Atherothrombotic Disease
Circulation,
April 24, 2007;
115(16):
2196 - 2207.
[Full Text]
[PDF]
|
|
|
|
|
|
|
Y. A. Senis, M. G. Tomlinson, A. Garcia, S. Dumon, V. L. Heath, J. Herbert, S. P. Cobbold, J. C. Spalton, S. Ayman, R. Antrobus, et al.
A Comprehensive Proteomics and Genomics Analysis Reveals Novel Transmembrane Proteins in Human Platelets and Mouse Megakaryocytes Including G6b-B, a Novel Immunoreceptor Tyrosine-based Inhibitory Motif Protein
Mol. Cell. Proteomics,
March 1, 2007;
6(3):
548 - 564.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. Wehner, C. N. Morrell, T. Reynolds, E. R. Rodriguez, and W. M. Baldwin III
Antibody and Complement in Transplant Vasculopathy
Circ. Res.,
February 2, 2007;
100(2):
191 - 203.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
Q. Ren, H. K. Barber, G. L. Crawford, Z. A. Karim, C. Zhao, W. Choi, C.-C. Wang, W. Hong, and S. W. Whiteheart
Endobrevin/VAMP-8 Is the Primary v-SNARE for the Platelet Release Reaction
Mol. Biol. Cell,
January 1, 2007;
18(1):
24 - 33.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
D. V. Gnatenko, P. L. Perrotta, and W. F. Bahou
Proteomic approaches to dissect platelet function: half the story
Blood,
December 15, 2006;
108(13):
3983 - 3991.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
E. M. Pasini, M. Kirkegaard, P. Mortensen, H. U. Lutz, A. W. Thomas, and M. Mann
In-depth analysis of the membrane and cytosolic proteome of red blood cells
Blood,
August 1, 2006;
108(3):
791 - 801.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
G. L. Hortin
The MALDI-TOF Mass Spectrometric View of the Plasma Proteome and Peptidome
Clin. Chem.,
July 1, 2006;
52(7):
1223 - 1237.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. Fujimi, M. P. MacConmara, A. A. Maung, Y. Zang, J. A. Mannick, J. A. Lederer, and P. H. Lapchak
Platelet depletion in mice increases mortality after thermal injury
Blood,
June 1, 2006;
107(11):
4399 - 4406.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. Tedgui and Z. Mallat
Cytokines in Atherosclerosis: Pathogenic and Regulatory Pathways
Physiol Rev,
April 1, 2006;
86(2):
515 - 581.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
R. Aslam, E. R. Speck, M. Kim, A. R. Crow, K. W. A. Bang, F. P. Nestel, H. Ni, A. H. Lazarus, J. Freedman, and J. W. Semple
Platelet Toll-like receptor expression modulates lipopolysaccharide-induced thrombocytopenia and tumor necrosis factor-{alpha} production in vivo
Blood,
January 15, 2006;
107(2):
637 - 641.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
B. Lo, L. Li, P. Gissen, H. Christensen, P. J. McKiernan, C. Ye, M. Abdelhaleem, J. A. Hayes, M. D. Williams, D. Chitayat, et al.
Requirement of VPS33B, a member of the Sec1/Munc18 protein family, in megakaryocyte and platelet {alpha}-granule biogenesis
Blood,
December 15, 2005;
106(13):
4159 - 4166.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
H. Schulze, M. Korpal, W. Bergmeier, J. E. Italiano Jr, S. M. Wahl, and R. A. Shivdasani
Interactions between the megakaryocyte/platelet-specific {beta}1 tubulin and the secretory leukocyte protease inhibitor SLPI suggest a role for regulated proteolysis in platelet functions
Blood,
December 15, 2004;
104(13):
3949 - 3957.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. M. Rox, P. Bugert, J. Muller, A. Schorr, P. Hanfland, K. Madlener, H. Kluter, and B. Potzsch
Gene Expression Analysis in Platelets from a Single Donor: Evaluation of a PCR-Based Amplification Technique
Clin. Chem.,
December 1, 2004;
50(12):
2271 - 2278.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. Brill, H. Elinav, and D. Varon
Differential role of platelet granular mediators in angiogenesis
Cardiovasc Res,
August 1, 2004;
63(2):
226 - 235.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
